INTRODUCTION: HIV vaccine efficacy trials conducted in suitable populations are anticipated in sub-Saharan Africa. We assessed the willingness to participate in future vaccine trials among individuals from fishing communities along Lake Victoria, Uganda. METHODS: From July to October 2012, we described a hypothetical vaccine trial to 328 (62.2% men) adults (18-49 years), at risk of HIV infection within 6 months of enrolment in a cohort and assessed their willingness to participate in the trial. Chi-square and logistic regression models were fitted to assess associations between vaccine trial attributes, participants' characteristics and willingness to participate. RESULTS: Overall, 99.4% expressed willingness to participate in the hypothetical HIV vaccine trial. This decreased marginally with introduction of particular vaccine trial attributes. Delaying pregnancy for 10 months and large blood draw had the largest effects on reducing willingness to participate to 93.5% (p=0.02) and 94.5% (p=0.01) respectively. All the vaccine trial attributes in combination reduced willingness to participate to 90.6%. This overall reduction in willingness to participate was significantly associated with gender and exchange of gifts for sex in multivariable analysis; women were more than three times as likely to have expressed unwillingness to participate in future vaccine trials as men (aOR=3.4, 95% CI: 1.55, 7.33) and participants who never received gifts in exchange for sex were more than four times as likely to have expressed unwillingness as those who received gifts for sex (aOR=4.5; 95%CI 1.30, 16.70). The main motivators of participation were access to HIV counselling and testing services (31.9%), HIV education (18.0%), hope of being prevented from acquiring HIV (16.6%) and health care (12.5%). CONCLUSION: Our study identifies an important population for inclusion in future HIV prevention trials and provides important insights into acceptability of trial procedures, differences in decisions of women and men and areas for further participant education.
INTRODUCTION: HIV vaccine efficacy trials conducted in suitable populations are anticipated in sub-Saharan Africa. We assessed the willingness to participate in future vaccine trials among individuals from fishing communities along Lake Victoria, Uganda. METHODS: From July to October 2012, we described a hypothetical vaccine trial to 328 (62.2% men) adults (18-49 years), at risk of HIV infection within 6 months of enrolment in a cohort and assessed their willingness to participate in the trial. Chi-square and logistic regression models were fitted to assess associations between vaccine trial attributes, participants' characteristics and willingness to participate. RESULTS: Overall, 99.4% expressed willingness to participate in the hypothetical HIV vaccine trial. This decreased marginally with introduction of particular vaccine trial attributes. Delaying pregnancy for 10 months and large blood draw had the largest effects on reducing willingness to participate to 93.5% (p=0.02) and 94.5% (p=0.01) respectively. All the vaccine trial attributes in combination reduced willingness to participate to 90.6%. This overall reduction in willingness to participate was significantly associated with gender and exchange of gifts for sex in multivariable analysis; women were more than three times as likely to have expressed unwillingness to participate in future vaccine trials as men (aOR=3.4, 95% CI: 1.55, 7.33) and participants who never received gifts in exchange for sex were more than four times as likely to have expressed unwillingness as those who received gifts for sex (aOR=4.5; 95%CI 1.30, 16.70). The main motivators of participation were access to HIV counselling and testing services (31.9%), HIV education (18.0%), hope of being prevented from acquiring HIV (16.6%) and health care (12.5%). CONCLUSION: Our study identifies an important population for inclusion in future HIV prevention trials and provides important insights into acceptability of trial procedures, differences in decisions of women and men and areas for further participant education.
Authors: Esther Kissling; Edward H Allison; Janet A Seeley; Steven Russell; Max Bachmann; Stanley D Musgrave; Simon Heck Journal: AIDS Date: 2005-11-18 Impact factor: 4.177
Authors: D Serwadda; R D Mugerwa; N K Sewankambo; A Lwegaba; J W Carswell; G B Kirya; A C Bayley; R G Downing; R S Tedder; S A Clayden; R A Weiss; A G Dalgleish Journal: Lancet Date: 1985-10-19 Impact factor: 79.321
Authors: G R Seage; S E Holte; D Metzger; B A Koblin; M Gross; C Celum; M Marmor; G Woody; K H Mayer; C Stevens; F N Judson; D McKirnan; A Sheon; S Self; S P Buchbinder Journal: Am J Epidemiol Date: 2001-04-01 Impact factor: 4.897
Authors: B A Koblin; P Heagerty; A Sheon; S Buchbinder; C Celum; J M Douglas; M Gross; M Marmor; K Mayer; D Metzger; G Seage Journal: AIDS Date: 1998-05-07 Impact factor: 4.177
Authors: Eugene Ruzagira; Symon Wandiembe; Andrew Abaasa; Jonathan Levin; Agnes Bwanika; Ubaldo Bahemuka; Matthew A Price; Anatoli Kamali Journal: PLoS One Date: 2011-06-03 Impact factor: 3.240
Authors: Annet Nanvubya; Julius Ssempiira; Juliet Mpendo; Ali Ssetaala; Annet Nalutaaya; Mathias Wambuzi; Paul Kitandwe; Bernard S Bagaya; Sabrina Welsh; Stephen Asiimwe; Leslie Nielsen; Fredrick Makumbi; Noah Kiwanuka Journal: PLoS One Date: 2015-10-29 Impact factor: 3.240
Authors: Theodora Mbunda; Edith A M Tarimo; Guerino Chalamilla; Muhammad Bakari; Eric Sandström; Asli Kulane Journal: PLoS One Date: 2016-12-20 Impact factor: 3.240
Authors: Lucy Chimoyi; Mphatso Kamndaya; Emilie Venables; Nina von Knorring; Jonathan Stadler; Catherine MacPhail; Matthew F Chersich; Helen Rees; Sinead Delany-Moretlwe Journal: BMC Public Health Date: 2017-07-04 Impact factor: 3.295
Authors: Theodora Mbunda; Muhammad Bakari; Edith A M Tarimo; Eric Sandstrom; Asli Kulane Journal: Glob Health Action Date: 2014-02-25 Impact factor: 2.640
Authors: Noah Kiwanuka; Juliet Mpendo; Annet Nalutaaya; Matthias Wambuzi; Annet Nanvubya; Paul K Kitandwe; Enoch Muyanja; Julius Ssempiira; Apolo Balyegisawa; Ali Ssetaala Journal: BMC Public Health Date: 2014-09-22 Impact factor: 3.295
Authors: Ogbonnaya S Njoku; Mark M Manak; Robert J O'Connell; Ashley L W Shutt; Jennifer A Malia; Richard A Heipertz; Sodsai Tovanabutra; Mark J Milazzo; Gideon Akindiran Akintunde; Abraham S Alabi; Aminu Suleiman; Amos A Ogundeji; Terfa S Kene; Robbie Nelson; Ojor R Ayemoba; Darrell E Singer; Merlin L Robb; Sheila A Peel; Nelson L Michael Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Annet Nanvubya; Rhoda Kitty Wanyenze; Onesmus Kamacooko; Teddy Nakaweesa; Juliet Mpendo; Barbarah Kawoozo; Francis Matovu; Sarah Nabukalu; Geoffrey Omoding; Jed Kaweesi; John Ndugga; Bernard Bagaya; Kundai Chinyenze; Matt Price; Jean Pierre Van Geertruyden Journal: J Prim Care Community Health Date: 2020 Jan-Dec